Trump Makes History: Medical Marijuana Reclassified as Less-Dangerous Drug in Federal Shift

Trump Administration Moves Medical Marijuana From Schedule I to Schedule III

President Donald Trump’s acting attorney general signed a landmark order on Thursday. The order reclassifies state-licensed medical marijuana as a less-dangerous drug. Todd Blanche signed the directive, delivering a major federal policy shift. Advocates have long argued that cannabis should never have shared a classification with heroin.

The order does not legalize marijuana for medical or recreational use under U.S. law. However, it changes the way the federal government regulates cannabis. It moves licensed medical marijuana from Schedule I to the less restrictive Schedule III. Schedule I applies to drugs with no accepted medical use and a high potential for abuse.

Schedule III carries far less restrictive federal oversight than Schedule I. Any marijuana-derived medicine the Food and Drug Administration approves also falls under Schedule III. The Trump administration did not create full federal legalization of cannabis with this reclassification. It did, however, create a significantly more permissive federal framework for licensed operators.

What the Order Actually Changes

The order changes the regulatory framework for licensed medical marijuana operators. It sets up an expedited registration system for state-licensed producers. Distributors must also register with the U.S. Drug Enforcement Administration. The order largely legitimizes medical marijuana programs across the 40 states that have adopted them.

Cannabis researchers also benefit directly from the new order. The order makes clear that researchers will not face penalties. They can now obtain state-licensed marijuana or marijuana-derived products for use in their work. This removes a significant barrier that had chilled scientific investigation for decades.

The order also grants state-licensed medical marijuana companies a major financial windfall. For the first time, these companies can deduct business expenses on their federal taxes. The tax barrier had long frustrated legal cannabis businesses. Companies operating within state law still faced harsh federal tax penalties before this change.

Blanche Frames Action as Fulfilling Trump’s Promise

Acting Attorney General Todd Blanche spoke directly about the order’s significance. He said the Department of Justice was “delivering on President Trump’s promise.” The promise centred on expanding Americans’ access to medical treatment options. Blanche made clear this was a deliberate and targeted policy decision.

“This rescheduling action allows for research on the safety and efficacy of this substance,” Blanche said. He added that it would ultimately provide patients with better care. Doctors would also gain access to more reliable information, he noted. His statement framed the move as a public health improvement, not merely a regulatory adjustment.

Trump had urged his administration in December to move as fast as possible on cannabis reclassification. Officials spent months working through the required legal and regulatory processes. On Saturday, Trump signed an unrelated executive order about psychedelics. During that signing, he appeared to express frustration at how long the marijuana reclassification was taking.

A Policy Shift Decades in the Making

The U.S. government has maintained marijuana prohibition since the Marijuana Tax Act of 1937. That is approximately 89 years of continuous federal prohibition. The Trump administration made the most significant federal shift in that long history with this order. It marks a dramatic break from nearly nine decades of unyielding federal cannabis policy.

Nearly all U.S. states have approved cannabis use in some form. Yet the federal government had maintained its hardline stance throughout. The disconnect between state and federal law created enormous legal uncertainty. Licensed businesses operated legally at the state level but faced federal restrictions simultaneously.

The new Schedule III classification resolves some of that contradiction directly. It legitimises state-licensed operations in a way federal law never previously recognised. The 40 states with medical marijuana programs now have a clearer federal pathway. Their licensed operators can interact with federal systems through the expedited DEA registration process.

Tax Relief Opens New Chapter for Cannabis Industry

The financial impact of the order extends well beyond regulatory status. The ability to deduct business expenses on federal taxes transforms the economics of the cannabis industry. Previously, federal tax law blocked these deductions for cannabis businesses. That rule applied even to companies fully compliant with their state’s laws.

Legal cannabis operators had described the tax restriction as deeply punishing. It forced them to pay taxes on gross revenue rather than net profit. The new order removes this burden for state-licensed medical marijuana companies. Industry observers expect this change to significantly improve the financial health of licensed operators.

The order also eases several other barriers to researching cannabis. Scientists and researchers can now access state-licensed marijuana products without fear of federal penalty. This could accelerate clinical studies into the medical benefits and risks of cannabis. Better data will ultimately help both patients and physicians make more informed decisions.

Scope and Limitations of the Reclassification

The order applies specifically to state-licensed medical marijuana. It does not extend protections to recreational cannabis operators or unlicensed sellers. Federal prohibition of marijuana outside these parameters remains in force. The administration drew a careful line between licensed medical use and broader recreational markets.

The DEA registration system will govern which operators qualify for the new framework. State-licensed producers and distributors must enrol in this expedited process. Only those who register will benefit from the Schedule III protections. The administration built a structured compliance mechanism into the order from the outset.

Advocates welcomed the shift while noting it stops short of full federal legalisation. Many had pushed for complete descheduling of cannabis from federal controlled substance lists. The reclassification still represents the most consequential federal cannabis policy change in modern U.S. history. It opens a new chapter in the long and contested debate over marijuana’s legal status in America.